ATE242238T1 - Chinolin- und chinazolin-verbindungen von therapeutischem nutzen, insbesondere zur behandlung von gutartiger prostatahyperplasie - Google Patents

Chinolin- und chinazolin-verbindungen von therapeutischem nutzen, insbesondere zur behandlung von gutartiger prostatahyperplasie

Info

Publication number
ATE242238T1
ATE242238T1 AT98904058T AT98904058T ATE242238T1 AT E242238 T1 ATE242238 T1 AT E242238T1 AT 98904058 T AT98904058 T AT 98904058T AT 98904058 T AT98904058 T AT 98904058T AT E242238 T1 ATE242238 T1 AT E242238T1
Authority
AT
Austria
Prior art keywords
quinoline
treatment
therapeutic utility
benign prostate
prostate hyperplasia
Prior art date
Application number
AT98904058T
Other languages
English (en)
Inventor
David Nathan Abraham Fox
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE242238T1 publication Critical patent/ATE242238T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT98904058T 1997-01-11 1998-01-06 Chinolin- und chinazolin-verbindungen von therapeutischem nutzen, insbesondere zur behandlung von gutartiger prostatahyperplasie ATE242238T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9700504.5A GB9700504D0 (en) 1997-01-11 1997-01-11 Pharmaceutical compounds
PCT/EP1998/000143 WO1998030560A1 (en) 1997-01-11 1998-01-06 Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of begnin prostatic hyperplasia

Publications (1)

Publication Number Publication Date
ATE242238T1 true ATE242238T1 (de) 2003-06-15

Family

ID=10805838

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98904058T ATE242238T1 (de) 1997-01-11 1998-01-06 Chinolin- und chinazolin-verbindungen von therapeutischem nutzen, insbesondere zur behandlung von gutartiger prostatahyperplasie

Country Status (45)

Country Link
US (4) US6169093B1 (de)
EP (1) EP0968208B1 (de)
JP (1) JP3357677B2 (de)
KR (1) KR100347472B1 (de)
CN (2) CN1093858C (de)
AP (1) AP819A (de)
AR (1) AR010396A1 (de)
AT (1) ATE242238T1 (de)
AU (1) AU724990B2 (de)
BG (1) BG63918B1 (de)
BR (1) BR9807068A (de)
CA (1) CA2277473C (de)
CZ (1) CZ295580B6 (de)
DE (1) DE69815313T2 (de)
DK (1) DK0968208T3 (de)
DZ (1) DZ2394A1 (de)
EA (1) EA002851B1 (de)
ES (1) ES2198695T3 (de)
GB (1) GB9700504D0 (de)
HK (2) HK1025327A1 (de)
HN (1) HN1998000002A (de)
HR (1) HRP980010B1 (de)
HU (1) HUP0000942A3 (de)
ID (1) ID21863A (de)
IL (1) IL130762A (de)
IS (1) IS2012B (de)
MA (1) MA26465A1 (de)
MY (1) MY119623A (de)
NO (1) NO318609B1 (de)
NZ (1) NZ336302A (de)
OA (1) OA11074A (de)
PA (1) PA8444301A1 (de)
PE (1) PE44499A1 (de)
PL (1) PL334678A1 (de)
PT (1) PT968208E (de)
SA (1) SA97180705B1 (de)
SI (1) SI0968208T1 (de)
SK (1) SK284779B6 (de)
TN (1) TNSN98004A1 (de)
TR (1) TR199901604T2 (de)
TW (1) TW444013B (de)
UA (1) UA62945C2 (de)
WO (1) WO1998030560A1 (de)
YU (1) YU31699A (de)
ZA (1) ZA98166B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9700504D0 (en) 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
GB9708917D0 (en) * 1997-05-01 1997-06-25 Pfizer Ltd Compounds useful in therapy
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
CN1214029C (zh) * 2000-03-03 2005-08-10 辉瑞大药厂 4－氨基－6,7－二甲氧基－2－(5－甲磺酰氨基－1,2,3,4－四氢异喹啉－2－基)－5－(2－吡啶基)喹唑啉甲磺酸盐及多晶形物
ATE309240T1 (de) 2000-08-31 2005-11-15 Hoffmann La Roche Chinazolin-derivate als alpha-1 adrenerge antagonisten
WO2002053558A1 (en) * 2001-01-02 2002-07-11 F.Hoffman-La Roche Ag Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists
US6900220B2 (en) 2001-01-02 2005-05-31 Syntex (U.S.A.) Llc Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists
US6734303B2 (en) 2001-05-18 2004-05-11 Pfizer Inc. Process for the production of quinazolines
GB0112061D0 (en) * 2001-05-18 2001-07-11 Pfizer Ltd Process for the production of quinazolines
GB0124455D0 (en) * 2001-10-11 2001-12-05 Pfizer Ltd Pharmaceutical formulations
US7163696B2 (en) 2001-10-11 2007-01-16 Pfizer Inc. Pharmaceutical formulations
GB0206033D0 (en) * 2002-03-14 2002-04-24 Pfizer Ltd Compounds useful in therapy
EP1521747B1 (de) 2002-07-15 2018-09-05 Symphony Evolution, Inc. Modulatoren von rezeptor-typ-kinase und anwendungsverfahren
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
GB0221579D0 (en) * 2002-09-17 2002-10-23 Pfizer Ltd Combinations of atorvastatin and, adrenergic receptor antagonists
GB0221582D0 (en) * 2002-09-17 2002-10-23 Pfizer Ltd Method of treatment
MXPA05002004A (es) 2002-09-26 2005-04-28 Pfizer Derivados de pirazol.
GB0225908D0 (en) * 2002-11-06 2002-12-11 Pfizer Ltd Treatment of female sexual dysfunction
CA2509605C (en) 2002-12-13 2010-10-05 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
AU2004255585A1 (en) * 2003-07-02 2005-01-20 F. Hoffmann-La Roche Ag 5-substituted quinazolinone derivatives
US7291640B2 (en) 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
CA2537812C (en) 2003-09-26 2013-01-22 Exelixis, Inc. C-met modulators and method of use
WO2005089804A2 (en) * 2004-03-16 2005-09-29 Pfizer Limited Combinations of hmg-coa reductase inhibitors and alpha1 adrenergic receptor antagonists
KR20050092519A (ko) * 2004-03-16 2005-09-22 화이자 인코포레이티드 아토르바스타틴 및 α1-아드레날린성 수용체 길항제의 조합
AP2006003771A0 (en) 2004-04-30 2006-10-31 Warner Lambert Co Substituted morpholine compounds for the treatmentof central nervous system disorders
WO2008084493A2 (en) * 2007-01-09 2008-07-17 Unichem Laboratories Limited A novel process for the preparation of 2-halo-4-aminoquinazolines
JP2009126784A (ja) * 2007-11-19 2009-06-11 Mitsubishi Gas Chem Co Inc ２−ヨード−３，４−ジメトキシベンゾニトリルの製造方法。
JP2009126785A (ja) * 2007-11-19 2009-06-11 Mitsubishi Gas Chem Co Inc ２−ヨード−３，４−ジメトキシベンゾニトリルの製造方法
CA2995880C (en) 2009-01-16 2021-01-05 Exelixis, Inc. Processes for preparing n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
CN106458974B (zh) * 2014-03-24 2019-07-16 广东众生药业股份有限公司 作为smo抑制剂的喹啉衍生物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US875506A (en) * 1907-03-19 1907-12-31 Berry H Collins Guiding attachment for penholders.
GB1390014A (en) * 1971-05-07 1975-04-09 Koninklijke Pharma Fab Nv Process for the preparation of carbocyclic fused pyrimidine derivatives
US4026894A (en) * 1975-10-14 1977-05-31 Abbott Laboratories Antihypertensive agents
US4098788A (en) * 1977-06-20 1978-07-04 Bristol-Myers Company Process for preparing quinazolines
US4656174A (en) * 1982-07-24 1987-04-07 Pfizer Inc. Quinoline therapeutic agents
GB8506174D0 (en) * 1985-03-09 1985-04-11 Pfizer Ltd 4-amino-6 7-dimethoxy-2-piperazin-1-ylquinazoline derivatives
IT1270993B (it) * 1994-03-18 1997-05-26 Recordati Chem Pharm Derivati chinzolilamminici attivi come alfa-antagonisti
GB9526546D0 (en) * 1995-12-23 1996-02-28 Pfizer Ltd Compounds useful in therapy
GB9700504D0 (en) 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
GB9708917D0 (en) * 1997-05-01 1997-06-25 Pfizer Ltd Compounds useful in therapy
GB9711650D0 (en) 1997-06-05 1997-07-30 Pfizer Ltd Compounds useful in therapy

Also Published As

Publication number Publication date
CN1093858C (zh) 2002-11-06
HN1998000002A (es) 1999-01-08
CA2277473C (en) 2003-08-12
IL130762A0 (en) 2001-01-28
MY119623A (en) 2005-06-30
AU724990B2 (en) 2000-10-05
HRP980010B1 (en) 2002-06-30
WO1998030560A1 (en) 1998-07-16
HK1054389B (zh) 2005-10-14
PL334678A1 (en) 2000-03-13
US20030130259A1 (en) 2003-07-10
EA002851B1 (ru) 2002-10-31
US6653302B2 (en) 2003-11-25
IL130762A (en) 2005-12-18
HRP980010A2 (en) 1998-10-31
HUP0000942A3 (en) 2002-06-28
KR20000070022A (ko) 2000-11-25
AR010396A1 (es) 2000-06-07
US20020040028A1 (en) 2002-04-04
OA11074A (en) 2002-03-13
BG103560A (en) 2000-06-30
DK0968208T3 (da) 2003-07-28
SA97180705B1 (ar) 2005-12-26
HK1054389A1 (en) 2003-11-28
AP9801175A0 (en) 1998-01-31
DE69815313D1 (de) 2003-07-10
UA62945C2 (en) 2004-01-15
BG63918B1 (bg) 2003-06-30
KR100347472B1 (ko) 2002-08-07
ES2198695T3 (es) 2004-02-01
CN1243513A (zh) 2000-02-02
MA26465A1 (fr) 2004-12-20
HUP0000942A2 (hu) 2001-04-28
DZ2394A1 (fr) 2003-06-04
HK1025327A1 (en) 2000-11-10
GB9700504D0 (en) 1997-02-26
CZ9902436A3 (cs) 2000-10-11
BR9807068A (pt) 2000-05-02
IS5093A (is) 1999-06-25
EP0968208A1 (de) 2000-01-05
NO993396D0 (no) 1999-07-09
CN1403453A (zh) 2003-03-19
TNSN98004A1 (fr) 2005-03-15
IS2012B (is) 2005-05-13
SI0968208T1 (en) 2003-10-31
PE44499A1 (es) 1999-05-06
US6521629B2 (en) 2003-02-18
PA8444301A1 (es) 2000-05-24
NO993396L (no) 1999-07-09
US6365599B1 (en) 2002-04-02
EP0968208B1 (de) 2003-06-04
ZA98166B (en) 1999-07-09
JP2000507966A (ja) 2000-06-27
AP819A (en) 2000-04-03
PT968208E (pt) 2003-09-30
EA199900531A1 (ru) 2000-02-28
CA2277473A1 (en) 1998-07-16
ID21863A (id) 1999-08-05
CN1191249C (zh) 2005-03-02
SK284779B6 (sk) 2005-11-03
DE69815313T2 (de) 2003-12-11
JP3357677B2 (ja) 2002-12-16
YU31699A (sh) 2001-07-10
US6169093B1 (en) 2001-01-02
TW444013B (en) 2001-07-01
NZ336302A (en) 2000-08-25
TR199901604T2 (xx) 1999-12-21
NO318609B1 (no) 2005-04-18
SK90799A3 (en) 2001-03-12
AU6208898A (en) 1998-08-03
CZ295580B6 (cs) 2005-08-17

Similar Documents

Publication Publication Date Title
ATE242238T1 (de) Chinolin- und chinazolin-verbindungen von therapeutischem nutzen, insbesondere zur behandlung von gutartiger prostatahyperplasie
DE60023982D1 (de) System zur Behandlung von benigner Prostatahyperplasie
NO20014560L (no) Quinasoliner og terapautisk anvendelse derav
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
ATE300597T1 (de) Behandlung von geweben
ATE527022T1 (de) Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie
DE69738045D1 (de) Verwendung von cetrorelix zur behandlung von benigne prostatahypertrophie und prostatakrebs
DE69925306D1 (de) Behandlung von kohlenwasserstoffgas
DE69821667D1 (de) Kardioverter zur Behandlung von Vorhofflattern
ATE239509T1 (de) Konjugate zur behandlung von prostatakrebs
DE69806801T2 (de) Galenische präparation zur prävention und behandlung von hepatokarzinomen
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
DE50212701D1 (de) Bestrahlungsanordnung zur behandlung von akne und aknenarben
DE60030554D1 (de) Verwendungen von et743 zur behandlung von krebs
DE60009888T2 (de) Substituierte 3-cyano-[1.7], [1.5] und [1.8]naphthyridininhibitoren von tyrosin kinasen
DE69825319D1 (de) Präparat zur vorbeugung und behandlung von entzündungen
DE60001255T2 (de) Zusammensetzung zur Behandlung von Polyesterfaser
ATE250580T1 (de) Substituierte pyridino-arylpiperazine zur behandlung benigner prostatahyperplasie
ATE226440T1 (de) Zusammensetzung zur behandlung von psoriasis
DE69934336D1 (de) Verwendung von halofuginone zur behandlung von urethralstriktur
ATE280156T1 (de) Phthalimido arylpiperazinen als alpha 1a rezeptor antagonisten nützlich zur behandlung von gutartigen prostatahyperplasia
DE59911556D1 (de) Arzneimittel zur vermeidung oder behandlung von papillomavirus-spezifischem tumor
ATE204167T1 (de) Antikonvulsive derivate zur behandlung von psoriasis
GB9810895D0 (en) Combination therapy for the treatment of benign prostatic hyperplasia
UA25095A (uk) Ліhімеhт для лікуваhhя каhдидозhого і змішаhого вульвовагіhіту

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0968208

Country of ref document: EP

REN Ceased due to non-payment of the annual fee